Brief: Tiziana Life Sciences Starts Enrollment Of The First Patient Cohort In Its Intermediate Size Patient Population Expanded Access Program To Evaluate Foralumab In Non-Active Secondary Multiple Sclerosis Patients
26/10/2022 12:09
Oct 26 (Reuters) - Tiziana Life Sciences Ltd TLSA.O :
* TIZIANA LIFE SCIENCES STARTS ENROLLMENT OF THE FIRST
PATIENT
COHORT IN ITS INTERMEDIATE SIZE PATIENT POPULATION EXPANDED
ACCESS PROGRAM TO EVALUATE FORALUMAB IN NON-ACTIVE SECONDARY
MULTIPLE SCLEROSIS PATIENTS
Source text for Eikon: ID:nGNX6lDKtr
Further company coverage: TLSA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tiziana Life Sciences
See all newsTiziana's experimental MS treatment meets main goals in mid-stage study
Brief: Tiziana Life Sciences - Submits Request To FDA For Orphan Drug Designation For Intranasal Foralumab For Msa
Brief: Tiziana Announces Last Patient Completes Last Visit In Phase 2A Inform-MS Trial Of Intranasal Foralumab
Brief: Tiziana Announces Last Patient Successfully Dosed In Its Phase 2 Inform-MS Trial
Brief: Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis